Candel Therapeutics (CADL) EBITDA: 2020-2023
Historic EBITDA for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$10.3 million.
- Candel Therapeutics' EBITDA fell 27.37% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$33.4 million for FY2024, which is 13.08% up from last year.
- Per Candel Therapeutics' latest filing, its EBITDA stood at -$10.3 million for Q4 2023, which was down 16.44% from -$8.9 million recorded in Q3 2023.
- Over the past 5 years, Candel Therapeutics' EBITDA peaked at $1.6 million during Q4 2021, and registered a low of -$16.2 million during Q3 2021.
- Moreover, its 3-year median value for EBITDA was -$8.9 million (2022), whereas its average is -$8.1 million.
- In the last 5 years, Candel Therapeutics' EBITDA skyrocketed by 115.16% in 2021 and then plummeted by 607.58% in 2022.
- Quarterly analysis of 4 years shows Candel Therapeutics' EBITDA stood at -$10.5 million in 2020, then spiked by 115.16% to $1.6 million in 2021, then crashed by 607.58% to -$8.1 million in 2022, then decreased by 27.37% to -$10.3 million in 2023.
- Its EBITDA stands at -$10.3 million for Q4 2023, versus -$8.9 million for Q3 2023 and -$9.6 million for Q2 2023.